I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
Rivista di Ostetricia e Ginecologia
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index
Minerva Ginecologica 2014 Ottobre;66(5):479-95
lingua: Italiano, Inglese
Contraception containing estradiol valerate and dienogest – Advantages, adherence and user satisfaction
Graziottin A. ✉
Center for Gynecology and Medical Sexology, San Raffaele Resnati Hospital, Milan, Italy
The contraceptive pill containing estradiol valerate and dienogest meets women’s requests for: a more natural contraceptive, that is reliable and easy to use, with positive cosmetic effects; less intense and shorter bleeding, reduced anaemia and increased vital energy; reduced dysmenorrhoea and all the specific cycle-related symptoms linked to a drop in oestrogen and the related systemic inflammation, the result of a hormone free interval (HFI) of just two days; with a good impact on sexuality and overall well-being, all associated with a high level of efficacy: (uncorrected Pearl Index: 0.79; corrected: 0.42).
BACKGROUND: Women would prefer more natural hormonal contraception, with high reliability, good tolerability, a simple dosing schedule and possibly some health advantages.
AIM: To evaluate what the pill containing estradiol valerate and dienogest can offer women and the best way to communicate this opportunity, after 4 years of growing clinical use.
METHOD: A review of literature plus the Author‘s clinical experience.
RESULTS: The new pill containing estradiol valerate and dienogest may satisfy women’s need for: a more natural hormonal contraceptive with a low hormone dosage, high reliability and good tolerability; a simple dosing schedule (one pill per day for 28 days); a positive cosmetic effect on the skin; lighter and shorter withdrawal bleeding, improved anaemia, less fatigue and higher vital energy; reduced dysmenorrhoea and a dramatic reduction in all symptoms thanks to a shorter Hormone Free Interval (HFI) of just two days. The new pill is an option for all women taking hormonal contraception who would like a more natural choice; for those who have never used hormonal contraception and may consider this new opportunity positively, for those who suffer from various menstrual symptoms, related inflammation (“a shorter HFI means much fewer or no symptoms”) and, possibly for pre-menopausal women, an opportunity to combine excellent contraception with a definite improvement in their well-being.
CONCLUSION: The pill containing estradiol valerate and dienogest is a contraceptive option that may satisfy women’s demands for a more natural contraceptive while offering high reliability, good tolerability, a simple dosing schedule, lighter and shorter withdrawal bleeding, improved anaemia and a reduction in cycle-related symptoms thanks to a shorter Hormone Free Interval, and improved sexuality and general well-being. Communication should focus on women’s priorities regarding contraception and their pursuit of a better quality of life while on OC.